These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 31322413)
41. Chemotherapy for meningiomas. Kyritsis AP J Neurooncol; 1996 Sep; 29(3):269-72. PubMed ID: 8858533 [TBL] [Abstract][Full Text] [Related]
42. Long-term outcome after radiotherapy in patients with atypical and malignant meningiomas--clinical results in 85 patients treated in a single institution leading to optimized guidelines for early radiation therapy. Adeberg S; Hartmann C; Welzel T; Rieken S; Habermehl D; von Deimling A; Debus J; Combs SE Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):859-64. PubMed ID: 22137023 [TBL] [Abstract][Full Text] [Related]
43. Hydroxyurea chemotherapy in the treatment of meningiomas. Newton HB Neurosurg Focus; 2007; 23(4):E11. PubMed ID: 17961035 [TBL] [Abstract][Full Text] [Related]
44. Recent advances in the management of atypical meningiomas. Messerer M; Richoz B; Cossu G; Dhermain F; Hottinger AF; Parker F; Levivier M; Daniel RT Neurochirurgie; 2016 Aug; 62(4):213-22. PubMed ID: 27370103 [TBL] [Abstract][Full Text] [Related]
45. A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Aizer AA; Abedalthagafi M; Bi WL; Horvath MC; Arvold ND; Al-Mefty O; Lee EQ; Nayak L; Rinne ML; Norden AD; Reardon DA; Wen PY; Ligon KL; Ligon AH; Beroukhim R; Dunn IF; Santagata S; Alexander BM Neuro Oncol; 2016 Feb; 18(2):269-74. PubMed ID: 26323607 [TBL] [Abstract][Full Text] [Related]
46. Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases. Palma L; Celli P; Franco C; Cervoni L; Cantore G Neurosurg Focus; 1997 Apr; 2(4):e3. PubMed ID: 15096007 [TBL] [Abstract][Full Text] [Related]
47. Surgical Resection and Interstitial Iodine-125 Brachytherapy for High-Grade Meningiomas: A 25-Year Series. Magill ST; Lau D; Raleigh DR; Sneed PK; Fogh SE; McDermott MW Neurosurgery; 2017 Mar; 80(3):409-416. PubMed ID: 27258768 [TBL] [Abstract][Full Text] [Related]
48. Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Mazza E; Brandes A; Zanon S; Eoli M; Lombardi G; Faedi M; Franceschi E; Reni M Cancer Chemother Pharmacol; 2016 Jan; 77(1):115-20. PubMed ID: 26659583 [TBL] [Abstract][Full Text] [Related]
49. Treatment Response and Prognosis After Recurrence of Atypical Meningiomas. Cao X; Hao S; Wu Z; Wang L; Jia G; Zhang L; Zhang J World Neurosurg; 2015 Oct; 84(4):1014-9. PubMed ID: 26038336 [TBL] [Abstract][Full Text] [Related]
50. Hydroxyurea chemotherapy for unresectable or residual meningioma. Newton HB; Slivka MA; Stevens C J Neurooncol; 2000 Sep; 49(2):165-70. PubMed ID: 11206012 [TBL] [Abstract][Full Text] [Related]
51. Gamma Knife Radiosurgery for Atypical and Anaplastic Meningiomas. Wang WH; Lee CC; Yang HC; Liu KD; Wu HM; Shiau CY; Guo WY; Pan DH; Chung WY; Chen MT World Neurosurg; 2016 Mar; 87():557-64. PubMed ID: 26485417 [TBL] [Abstract][Full Text] [Related]
52. "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Perry A; Scheithauer BW; Stafford SL; Lohse CM; Wollan PC Cancer; 1999 May; 85(9):2046-56. PubMed ID: 10223247 [TBL] [Abstract][Full Text] [Related]
53. Chordoid meningiomas: incidence and clinicopathological features of a case series over 18 years. Di Ieva A; Laiq S; Nejad R; Schmitz EM; Fathalla H; Karamchandani J; Munoz DG; Cusimano MD Neuropathology; 2015 Apr; 35(2):137-47. PubMed ID: 25378105 [TBL] [Abstract][Full Text] [Related]
54. Different responses of benign and atypical meningiomas to gamma-knife radiosurgery: report of two cases with immunohistochemical analysis. Kawashima M; Suzuki SO; Ikezaki K; Matsushima T; Fukui M; Iwaki T Brain Tumor Pathol; 2001; 18(2):61-6. PubMed ID: 11908875 [TBL] [Abstract][Full Text] [Related]
55. Inflammatory response and meningioma tumorigenesis and the effect of cyclooxygenase-2 inhibitors. Ragel BT; Jensen RL; Couldwell WT Neurosurg Focus; 2007; 23(4):E7. PubMed ID: 17961044 [TBL] [Abstract][Full Text] [Related]
56. Intrinsic expression of drug resistance-associated factors in meningiomas. Tews DS; Fleissner C; Tiziani B; Gaumann AK Appl Immunohistochem Mol Morphol; 2001 Sep; 9(3):242-9. PubMed ID: 11556752 [TBL] [Abstract][Full Text] [Related]
57. Meningioma grading: an analysis of histologic parameters. Perry A; Stafford SL; Scheithauer BW; Suman VJ; Lohse CM Am J Surg Pathol; 1997 Dec; 21(12):1455-65. PubMed ID: 9414189 [TBL] [Abstract][Full Text] [Related]
58. Diagnosis and treatment of atypical and anaplastic meningiomas: a review. Modha A; Gutin PH Neurosurgery; 2005 Sep; 57(3):538-50; discussion 538-50. PubMed ID: 16145534 [TBL] [Abstract][Full Text] [Related]
59. Anaplastic meningioma: progression from atypical and chordoid morphotype with morphologic spectral variation at recurrence. Bollag RJ; Vender JR; Sharma S Neuropathology; 2010 Jun; 30(3):279-87. PubMed ID: 19780983 [TBL] [Abstract][Full Text] [Related]
60. Long-term survival analysis of atypical meningiomas: survival rates, prognostic factors, operative and radiotherapy treatment. Hammouche S; Clark S; Wong AH; Eldridge P; Farah JO Acta Neurochir (Wien); 2014 Aug; 156(8):1475-81. PubMed ID: 24965072 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]